Chromogenic in-situ hybridization: A viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm

Modern Pathology

Volumn 19, Issue 4, 2006, Pages 481-487

  Hanna, Wedad M ^a   Kwok, Kevin ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

CISH; Concordance; FISH; HER2 testing; HER2 testing algorithm

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ALGORITHM; ARTICLE; BREAST CARCINOMA; CHROMOGENIC IN SITU HYBRIDIZATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; VALIDATION PROCESS;

ALGORITHMS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASMS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS;

EID: 33645298450     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800555     Document Type: Article

References (24)

1. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5:63-69.
2. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004;3:379-398.
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
4. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
6. Extra J-M, Cognetti F, Maraninchi D, et al. Trastuzumab (Herceptin®) plus docetaxel vs docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial (abstract 239). Eur J Cancer 2004;2(Suppl 3):125.
7. van de Vijver M. Emerging technologies for HER2 testing. Oncology 2002;63(Suppl 1):33-38.
8. Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003;16:173-182.
9. Leitzel K, Teramoto Y, Konrad K, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129-1135.
10. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90:1205-1211.
11. Hanna W. Testing for HER2 status. Oncology 2001;61(Suppl 2):22-30.
12. Lebeau A, Deimling D, Kaltz C, et al. HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001;19:354-363.
13. Piccart M, Lohrisch C, Di Leo A, et al. The predictive value of HER2 in breast cancer. Oncology 2001;61(Suppl 2):73-82.
14. de Laurentiis M, Arpino G, Massarelli E, et al. HER2 as predictive marker of resistance to endocrine treatment (ET) for advanced breast cancer (ABC): a meta-analysis of published studies (abstract 233). Breast Cancer Res Treat 2002;76(Suppl 1):S68.
15. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000;157:1467-1472.
16. Dandachi N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest 2002;82:1007-1014.
17. Zhao J, Wu R, Au A, et al. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol 2002;15:657-665.
18. Bilous M, Morey A, Armes J, et al. CISH or FISH? The interlaboratory reproducibility of CISH testing for HER2 and correlation with IHC and FISH results (abstract 160). Eur J Cancer Suppl 2004;2:100.
19. Peiro G, Mayr D, Hillemanns P, et al. Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. Mod Pathol 2004;17:227-287.
20. van de Vijver MJ, Bilous M, Hanna W, et al. Correlation of chromogenic in-situ hybridisation (CISH) with FISH and IHC for assessment of HER2 gene amplification: an international validation ring study (abstract 157). Eur J Cancer Suppl 2004;2:99.
21. Gong Y, Gilcrease M, Sneige N. Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod Pathol 2005;18:1015-1021.
22. Park K, Kim J, Lim S, et al. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol 2003;16:937-943.
23. van de Vijver M, Bilous M, Hanna W, et al. Chromogenic in-situ hybridisation (CISH) compared with FISH and IHC for detection of HER2 gene amplification: an international validation ring study. Breast Cancer Res Treat 2003;82(Suppl 1) (abstract 324) S75.
24. Varshney D, Zhou YY, Geller SA, et al. Determination of HER2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol 2004;121:70-77.